Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Tanya M. Spruill is active.

Publication


Featured researches published by Tanya M. Spruill.


Journal of Hypertension | 2008

Franz Volhard lecture: should doctors still measure blood pressure? The missing patients with masked hypertension

Thomas G. Pickering; William Gerin; Joseph E. Schwartz; Tanya M. Spruill; Karina W. Davidson

The traditional reliance on blood pressure (BP) measurement in the medical setting misses a significant number of individuals with masked hypertension, who have normal clinic BP but persistently high daytime BP when measured out of the office. We suggest that masked hypertension may be a precursor of clinically recognized sustained hypertension and is associated with increased cardiovascular risk compared with consistent normotension. We discuss factors that may contribute to clinic–daytime BP differences as well as the changing relationship between these two measures over time. Anxiety at the time of BP measurement and having been diagnosed as hypertensive appear to be two possible mechanisms. The identification of individuals with masked hypertension is of great clinical importance and requires out-of-office BP screening. Ambulatory BP monitoring is the best established technique for doing this, but home monitoring may be applicable in the future.


Neurology | 2016

Recognizing and preventing epilepsy-related mortality A call for action

Orrin Devinsky; Tanya M. Spruill; David J. Thurman; Daniel Friedman

Epilepsy is associated with a high rate of premature mortality from direct and indirect effects of seizures, epilepsy, and antiseizure therapies. Sudden unexpected death in epilepsy (SUDEP) is the second leading neurologic cause of total lost potential life-years after stroke, yet SUDEP may account for less than half of all epilepsy-related deaths. Some epilepsy groups are especially vulnerable: individuals from low socioeconomic status groups and those with comorbid psychiatric illness die more often than controls. Despite clear evidence of an important public health problem, efforts to assess and prevent epilepsy-related deaths remain inadequate. We discuss factors contributing to the underestimation of SUDEP and other epilepsy-related causes of death. We suggest the need for a systematic classification of deaths directly due to epilepsy (e.g., SUDEP, drowning), due to acute symptomatic seizures, and indirectly due to epilepsy (e.g., suicide, chronic effects of antiseizure medications). Accurately estimating the frequency of epilepsy-related mortality is essential to support the development and assessment of preventive interventions. We propose that educational interventions and public health campaigns targeting medication adherence, psychiatric comorbidity, and other modifiable risk factors may reduce epilepsy-related mortality. Educational campaigns regarding sudden infant death syndrome and fires, which kill far fewer Americans than epilepsy, have been widely implemented. We have done too little to prevent epilepsy-related deaths. Everyone with epilepsy and everyone who treats people with epilepsy need to know that controlling seizures will save lives.


Hypertension | 2016

Masked Hypertension and Incident Clinic Hypertension Among Blacks in the Jackson Heart Study

Marwah Abdalla; John N. Booth; Samantha R. Seals; Tanya M. Spruill; Anthony J. Viera; Keith M. Diaz; Mario Sims; Paul Muntner; Daichi Shimbo

Masked hypertension, defined as nonelevated clinic blood pressure (BP) and elevated out-of-clinic BP may be an intermediary stage in the progression from normotension to hypertension. We examined the associations of out-of-clinic BP and masked hypertension using ambulatory BP monitoring with incident clinic hypertension in the Jackson Heart Study, a prospective cohort of blacks. Analyses included 317 participants with clinic BP <140/90 mm Hg, complete ambulatory BP monitoring, who were not taking antihypertensive medication at baseline in 2000 to 2004. Masked daytime hypertension was defined as mean daytime blood pressure ≥135/85 mm Hg, masked night-time hypertension as mean night-time BP ≥120/70 mm Hg, and masked 24-hour hypertension as mean 24-hour BP ≥130/80 mm Hg. Incident clinic hypertension, assessed at study visits in 2005 to 2008 and 2009 to 2012, was defined as the first visit with clinic systolic/diastolic BP ≥140/90 mm Hg or antihypertensive medication use. During a median follow-up of 8.1 years, there were 187 (59.0%) incident cases of clinic hypertension. Clinic hypertension developed in 79.2% and 42.2% of participants with and without any masked hypertension, 85.7% and 50.4% with and without masked daytime hypertension, 79.9% and 43.7% with and without masked night-time hypertension, and 85.7% and 48.2% with and without masked 24-hour hypertension, respectively. Multivariable-adjusted hazard ratios (95% confidence interval) of incident clinic hypertension for any masked hypertension and masked daytime, night-time, and 24-hour hypertension were 2.13 (1.51–3.02), 1.79 (1.24–2.60), 2.22 (1.58–3.12), and 1.91 (1.32–2.75), respectively. These findings suggest that ambulatory BP monitoring can identify blacks at increased risk for developing clinic hypertension.


Epilepsia | 2015

Illness perceptions mediate the relationship between depression and quality of life in patients with epilepsy

Amanda J. Shallcross; Danielle A. Becker; Anuradha Singh; Daniel Friedman; Jacqueline Montesdeoca; Jacqueline A. French; Orrin Devinsky; Tanya M. Spruill

The current study examined whether negative illness perceptions help explain the link between depression and quality of life. Seventy patients with epilepsy completed standardized self‐report questionnaires measuring depression, illness perception, and quality of life (QOL). Illness perception statistically mediated the relationship between depression and QOL (Indirect effect (CI; confidence interval) = −.72, lower limit = −1.7, upper limit = −.22, p < .05). Results held with and without adjusting for potential confounding variables (age, sex, ethnicity, income, and seizure frequency) and when operationalizing depression as a continuous variable that indexed severity of symptoms or as a dichotomous variable that indexed criteria consistent with a diagnosis of major depressive disorder. This study is the first to suggest that illness perceptions may be a useful target in screening and intervention approaches in order to improve QOL among low‐income, racially/ethnically diverse patients with epilepsy.


The American Journal of Medicine | 2013

Racial and Ethnic Disparities in Disease Activity in Patients with Rheumatoid Arthritis

Jeffrey D. Greenberg; Tanya M. Spruill; Ying Shan; George W. Reed; Joel M. Kremer; Jeffrey Potter; Yusuf Yazici; Gbenga Ogedegbe; Leslie R. Harrold

BACKGROUND Observational studies of patients with rheumatoid arthritis have suggested that racial and ethnic disparities exist for minority populations. We compared disease activity and clinical outcomes across racial and ethnic groups using data from a large, contemporary US registry. METHODS We analyzed data from 2 time periods (2005-2007 and 2010-2012). The Clinical Disease Activity Index was examined as both a continuous measure and a dichotomous measure of disease activity states. Outcomes were compared in a series of cross-sectional and longitudinal multivariable regression models. RESULTS For 2005-2007, significant differences of mean disease activity level (P < .001) were observed across racial and ethnic groups. Over the 5-year period, modest improvements in disease activity were observed across all groups, including whites (3.7; 95% confidence interval [CI], 3.2-4.1) compared with African Americans (4.3; 95% CI, 2.7-5.8) and Hispanics (2.7; 95% CI, 1.2-4.3). For 2010-2012, significant differences of mean disease activity level persisted (P < .046) across racial and ethnic groups, ranging from 11.6 (95% CI, 10.4-12.8) in Hispanics to 10.7 (95% CI, 9.6-11.7) in whites. Remission rates remained significantly different across racial/ethnic groups across all models for 2010-2012, ranging from 22.7 (95% CI, 19.5-25.8) in African Americans to 27.4 (95% CI, 24.9-29.8) in whites. CONCLUSIONS Despite improvements in disease activity across racial and ethnic groups over a 5-year period, disparities persist in disease activity and clinical outcomes for minority groups versus white patients.


American Journal of Hypertension | 2013

Correlates of isolated nocturnal hypertension and target organ damage in a population-based cohort of African Americans: the Jackson Heart Study.

Gbenga Ogedegbe; Tanya M. Spruill; Daniel F. Sarpong; Charles Agyemang; William F. Chaplin; Amy Pastva; David Martins; Joseph Ravenell; Thomas G. Pickering

BACKGROUND African Americans have higher rates of nocturnal hypertension and less nocturnal blood pressure (BP) dipping compared with whites. Although nocturnal hypertension is associated with increased cardiovascular morbidity and mortality, its clinical significance among those with normal daytime BP is unclear. This paper reports the prevalence and correlates of isolated nocturnal hypertension (INH) in a population-based cohort of African Americans enrolled in the Jackson Heart Study (JHS). METHODS The study sample included 425 untreated, normotensive and hypertensive JHS participants who underwent 24-hour ambulatory BP monitoring (ABPM), echocardiography, and 24-hour urine collection. Multiple logistic regression and 1-way analysis of variance models were used to test the hypothesis that those with INH have worse target organ damage reflected by greater left ventricular (LV) mass and proteinuria compared with normotensive participants. RESULTS Based on 24-hour ABP profiles, 19.1% of participants had INH. In age and sex-adjusted models, participants with INH had greater LV mass compared with those who were normotensive (P = 0.02), as well as about 3 times the odds of LV hypertrophy and proteinuria (Ps < 0.10). However, multivariable adjustment reduced the magnitude and statistical significance of each of these differences. CONCLUSIONS INH was associated with increased LV mass compared with normo tension in a population-based cohort of African Americans enrolled in the JHS. There were trends toward a greater likelihood of LV hyper trophy and proteinuria among participants with INH vs. those who were normotensive. The clinical significance of the noted target organ damage should be explored in this population.


Epilepsy & Behavior | 2015

Psychosocial factors associated with medication adherence in ethnically and socioeconomically diverse patients with epilepsy

Amanda J. Shallcross; Danielle A. Becker; Anuradha Singh; Daniel Friedman; Rachel Jurd; Jacqueline A. French; Orrin Devinsky; Tanya M. Spruill

The current study examined psychosocial correlates of medication adherence in a socioeconomically and racially diverse sample of patients with epilepsy. Fifty-five patients with epilepsy completed standardized self-report questionnaires measuring depression, stress, social support, and medication and illness beliefs. Antiepileptic drug (AED) adherence was measured using the 8-item Morisky Medication Adherence Scale 36% reported poor adherence. We tested which psychosocial factors were independently and most strongly associated with AED adherence. Stress and depression were negatively correlated with adherence, while perceived social support was positively correlated with adherence (Ps<.05). When all three of these variables and relevant covariates in a multiple regression model were included, only perceived social support remained a significant predictor of adherence (P=.015). This study is one of the first to suggest the importance of targeting social support in screening and intervention approaches in order to improve AED adherence among low-income, racially/ethnically diverse patients with epilepsy.


Circulation | 2017

Incident Cardiovascular Disease Among Adults With Blood Pressure <140/90 mm Hg

Gabriel S. Tajeu; John N. Booth; Lisandro D. Colantonio; Rebecca F. Gottesman; George Howard; Daniel T. Lackland; Emily C. O’Brien; Suzanne Oparil; Joseph Ravenell; Monika M. Safford; Samantha R. Seals; Daichi Shimbo; Steven Shea; Tanya M. Spruill; Rikki M. Tanner; Paul Muntner

Background: Data from before the 2000s indicate that the majority of incident cardiovascular disease (CVD) events occur among US adults with systolic and diastolic blood pressure (SBP/DBP) ≥140/90 mm Hg. Over the past several decades, BP has declined and hypertension control has improved. Methods: We estimated the percentage of incident CVD events that occur at SBP/DBP <140/90 mm Hg in a pooled analysis of 3 contemporary US cohorts: the REGARDS study (Reasons for Geographic and Racial Differences in Stroke), the MESA (Multi-Ethnic Study of Atherosclerosis), and the JHS (Jackson Heart Study) (n=31 856; REGARDS=21 208; MESA=6779; JHS=3869). Baseline study visits were conducted in 2003 to 2007 for REGARDS, 2000 to 2002 for MESA, and 2000 to 2004 for JHS. BP was measured by trained staff using standardized methods. Antihypertensive medication use was self-reported. The primary outcome was incident CVD, defined by the first occurrence of fatal or nonfatal stroke, nonfatal myocardial infarction, fatal coronary heart disease, or heart failure. Events were adjudicated in each study. Results: Over a mean follow-up of 7.7 years, 2584 participants had incident CVD events. Overall, 63.0% (95% confidence interval [CI], 54.9−71.1) of events occurred in participants with SBP/DBP <140/90 mm Hg; 58.4% (95% CI, 47.7−69.2) and 68.1% (95% CI, 60.1−76.0) among those taking and not taking antihypertensive medication, respectively. The majority of events occurred in participants with SBP/DBP <140/90 mm Hg among those <65 years of age (66.7%; 95% CI, 60.5−73.0) and ≥65 years of age (60.3%; 95% CI, 51.0−69.5), women (61.4%; 95% CI, 49.9−72.9) and men (63.8%; 95% CI, 58.4−69.1), and for whites (68.7%; 95% CI, 66.1−71.3), blacks (59.0%; 95% CI, 49.5−68.6), Hispanics (52.7%; 95% CI, 45.1−60.4), and Chinese-Americans (58.5%; 95% CI, 45.2−71.8). Among participants taking antihypertensive medication with SBP/DBP <140/90 mm Hg, 76.6% (95% CI, 75.8−77.5) were eligible for statin treatment, but only 33.2% (95% CI, 32.1−34.3) were taking one, and 19.5% (95% CI, 18.5−20.5) met the SPRINT (Systolic Blood Pressure Intervention Trial) eligibility criteria and may benefit from a SBP target goal of 120 mm Hg. Conclusions: Although higher BP levels are associated with increased CVD risk, in the modern era, the majority of incident CVD events occur in US adults with SBP/DBP <140/90 mm Hg. While absolute risk and cost-effectiveness should be considered, additional CVD risk-reduction measures for adults with SBP/DBP <140/90 mm Hg at high risk for CVD may be warranted.


Annals of the Rheumatic Diseases | 2014

Association of medication beliefs and self-efficacy with adherence in urban Hispanic and African–American rheumatoid arthritis patients

Tanya M. Spruill; Gbenga Ogedegbe; Leslie R. Harrold; Jeffrey Potter; Jose U. Scher; Pamela Rosenthal; Jeffrey D. Greenberg

Adherence to rheumatoid arthritis (RA) medications varies widely but is frequently suboptimal1 and is particularly poor among racial/ethnic minority patients,2 which may help to explain the growing evidence of disparities in RA clinical outcomes.2 Beliefs about medications and self-efficacy perceptions (ie, confidence) regarding medication-taking behaviour are two modifiable patient factors that have been associated with adherence to RA medications in largely Caucasian study samples.1 Minority RA patients report more negative medication beliefs and lower self-efficacy compared with Caucasians,3–⇓5 but to our knowledge, the relationship between these psychological factors and medication adherence in these groups has not been reported. We addressed this question in a cross-sectional study of 56 urban Hispanic and African–American RA patients recruited consecutively from the waiting rooms of two NYU-affiliated rheumatology clinics in New York City (Bellevue Hospital and Hospital for Joint Diseases) between November 2012 and January 2013. All …


Progress in Cardiovascular Diseases | 2013

Economics of Psychosocial Factors in Patients with Cardiovascular Disease

Benjamin A. Rodwin; Tanya M. Spruill; Joseph A. Ladapo

Growing evidence supports a causal relationship between cardiovascular disease and psychosocial factors such as mental health and behavioral disorders, acute and chronic stress, and low socioeconomic status. While this has enriched our understanding of the interaction between cardiovascular risk factors, much less is known about its economic implications. In this review, we evaluate the economic impact of psychosocial factors in persons at risk for or diagnosed with cardiovascular disease. Most studies have focused on depression and almost uniformly conclude that patients with cardiovascular disease and comorbid depression use a greater number of ambulatory and hospital services and incur higher overall costs. Additionally, comorbid depression may also reduce employment productivity in patients with cardiovascular disease, further magnifying its economic impact. Recent randomized trials have demonstrated that innovative care delivery models that target depression may reduce costs or at least be cost neutral while improving quality of life. The growing population burden and overlap of cardiovascular disease, comorbid mental illness, and other psychosocial factors suggest that future research identifying cost-effective or cost-saving treatment models may have significant health and economic implications.

Collaboration


Dive into the Tanya M. Spruill's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Daichi Shimbo

Columbia University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Paul Muntner

University of Alabama at Birmingham

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

John N. Booth

University of Alabama at Birmingham

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mario Sims

University of Mississippi Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge